RENATA SIKORA

Dr. RENATA SIKORA

Department of Dental Medicine, Faculty of Dental Medicine and Health, JJ Strossmayer University of Osijek, Osijek, Osječko-Baranjska Županija, Croatia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAna Petrovic
Ana Petrovic
DIDunja Igrec
Dunja Igrec
KRKarla Rozac
Karla Rozac
KBKristina Bojanić
Kristina Bojanić
LKLucija Kuna
Lucija Kuna
MSMartina Smolic
Martina Smolic
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors. They are a promising therapeutic option for non-alcoholic fatty liver disease (NAFLD), the most common liver disease, associated with T2DM, obesity, and metabolic syndrome. GLP-1RAs have been approved for the treatment of T2DM and obesity, but not for NAFLD. Most recent clinical trials have suggested the importance of early pharmacologic intervention with GLP-1RAs in alleviating and limiting NAFLD, as well as highlighting the relative scarcity of in vitro studies on semaglutide, indicating the need for further research. However, extra-hepatic factors contribute to the GLP-1RA results of in vivo studies. Cell culture models of NAFLD can be helpful in eliminating extrahepatic effects on the alleviation of hepatic steatosis, modulation of lipid metabolism pathways, reduction of inflammation, and prevention of the progression of NAFLD to severe hepatic conditions. In this review article, we discuss the role of GLP-1 and GLP-1RA in the treatment of NAFLD using human hepatocyte models.

15 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
LPLuka Peric
Luka Peric
SVSonja Vukadin
Sonja Vukadin
APAna Petrovic
Ana Petrovic
LKLucija Kuna
Lucija Kuna
NPNora Puseljic
Nora Puseljic
MSMartina Smolic
Martina Smolic
Although we are lately witnessing major improvements in breast cancer treatment and patient outcomes, there is still a significant proportion of patients not receiving efficient therapy. More precisely, patients with triple-negative breast cancer or any type of metastatic disease. Currently available prognostic and therapeutic biomarkers are not always applicable and oftentimes lack precision. The science of glycans is a relatively new scientific approach to better characterize malignant transformation and tumor progression. In this review, we summarize the most important information about glycosylation characteristics in breast cancer cells and how different glycoproteins and enzymes involved in glycosylation could serve as more precise biomarkers, as well as new therapeutic targets.

20 March 2024 in Medicina
Verified
Journal Article
Open access
PDF file
KDKristina Duspara
Kristina Duspara
RSRENATA SIKORA
RENATA SIKORA
APAna Petrovic
Ana Petrovic
LKLucija Kuna
Lucija Kuna
AMAnita Matic
Anita Matic
MSMartina Smolic
Martina Smolic
Background and Objectives: Periodontitis is marked by the destruction of alveolar bone. Sclerostin (SOST) and dickkopf-1 (DKK-1) act as inhibitors of the Wingless-type (Wnt) signaling pathway, a key regulator of bone metabolism. Recent studies have suggested that statins play a role in bone resorption and formation by influencing Wnt signaling. The aim of this study was to determine the levels of SOST and DKK-1 in periodontal patients with and without peroral statins treatment in their therapy. Materials and Methods: A total of 79 patients with diagnosed periodontitis were divided into two groups: 39 patients on statin therapy (SP group) and 40 patients without statin therapy as a control group (P group). The periodontal clinical examination probing (pocket) depth (PD) and gingival recession (GR) were measured, and approximal plaque was detected, while vertical and horizontal bone resorption was measured using a panoramic radiograph image. Clinical attachment loss (CAL) values were calculated using PD and GR values. Gingival crevicular fluid (GCF) was collected and used for measuring SOST and DKK-1 levels. A questionnaire was used to assess lifestyle habits and statin intake. Patients’ medical records were used to obtain biochemical parameters. Results: There was no significant difference in sclerostin concentration between the SP and P group. DKK-1 values were significantly higher in the SP group compared to the control group (p = 0.04). Also, PD (p = 0.001) and GR (p = 0.03) were significantly higher in the SP group. The level of DKK-1 had a positive relationship with the PD, the greater the PD, the higher the level of DKK-1 (Rho = 0.350), while there was no significant association with other parameters. Conclusions: Peroral statins in periodontal patients are associated with GCF levels of DKK-1 but not with sclerostin levels.

27 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DLDomagoj Loinjak
Domagoj Loinjak
DMDamir Mihic
Damir Mihic
RSRobert Smolić
Robert Smolić
LMLana Maričić
Lana Maričić
IŠInes Šahinović
Ines Šahinović
AVAleksandar Včev
Aleksandar Včev
Acute respiratory distress syndrome (ARDS) is one of the most severe complications of the COVID-19 disease. The role of IL-33 and calpain 1 was previously described in lung infections and lung tissue damage. Our study examined the association between serum calpain 1 activity and IL-33 concentration in patients with COVID-19 ARDS. In the research, we included 80 subjects who had COVID-19 pneumonia and divided them into 2 groups: 40 subjects with ARDS and 40 subjects without ARDS. The basis of the research was the collection of subjects’ data and the sampling of peripheral venous blood. The concentration of IL-33 was determined by the ELISA method and the activity of calpain 1 by the fluorometry method. Our research showed elevated calpain 1 activity and IL-33 concentration in the serum of COVID-19 patients who developed ARDS compared to those who did not develop ARDS and a positive correlation between them was established. Further, a positive correlation was established between the examined parameters and the severity of the disease, proinflammatory markers, and the use of mechanical ventilation. These results indicate a possible association and role of calpain 1 and IL-33 with the development of ARDS in COVID-19 patients.

30 May 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Martina JuzbašićMartina Juzbašić
Martina Juzbašić
Matej TomasMatej Tomas
Matej Tomas
APAna Petrovic
Ana Petrovic
MHMarija Hefer
Marija Hefer
RSRENATA SIKORA
RENATA SIKORA
MSMartina Smolic
Martina Smolic
The interrelationship between periodontitis and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has attracted increasing attention due to the significant global rise in the prevalence of both conditions. Periodontitis, a chronic inflammatory disease, affects a substantial portion of the population and parallels the growing incidence of MASLD, which currently impacts nearly 30% of the global population. The updated nomenclature reflects a deeper understanding of the condition’s metabolic origins. This narrative review focuses on the shared pathophysiological mechanisms, particularly systemic inflammation, insulin resistance, and oxidative stress that may underlie the bidirectional relationship between these diseases. These mechanisms often act in concert to promote disease development. Unlike previous literature, this review emphasizes the hypothesis that chronic periodontal inflammation may not only mirror but also contribute to the systemic metabolic dysregulation observed in MASLD. We critically assess current evidence supporting this link by highlighting the role of inflammatory mediators in bridging oral and hepatic health, and by proposing an integrated, multidisciplinary approach to its early detection and management. The aim is to offer novel insights that can help develop better prevention strategies and more effective treatments for both diseases.

Verified
Journal Article
Open access
PDF file
TKTea Omanovic Kolaric
Tea Omanovic Kolaric
LKLucija Kuna
Lucija Kuna
MCMarina Covic
Marina Covic
HRHrvoje Roguljić
Hrvoje Roguljić
AMAnita Matic
Anita Matic
MSMartina Smolic
Martina Smolic
Liver fibrosis represents one of the greatest challenges in medicine. The fact that it develops with the progression of numerous diseases with high prevalence (NAFLD, viral hepatitis, etc.) makes liver fibrosis an even greater global health problem. Accordingly, it has received much attention from numerous researchers who have developed various in vitro and in vivo models to better understand the mechanisms underlying fibrosis development. All these efforts led to the discovery of numerous agents with antifibrotic properties, with hepatic stellate cells and the extracellular matrix at the center of these pharmacotherapeutic strategies. This review focuses on the current data on numerous in vivo and in vitro models of liver fibrosis and on various pharmacotherapeutic targets in the treatment of liver fibrosis.